Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2020

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2020		2019		2018
Analgesic	$	8,680	$	8,251	$	3,809
Anti-Psychosis		104,934		73,453		59,557
Cardiovascular		88,576		101,467		64,011
Central Nervous System		77,256		59,019		59,672
Endocrinology		—		197,522		245,929
Gastrointestinal		73,477		63,043		67,762
Infectious Disease		73,237		16,950		17,685
Migraine		44,266		41,592		54,015
Respiratory/Allergy/Cough/Cold		11,576		12,479		25,284
Urinary		4,225		6,755		8,068
Other		35,013		51,517		58,936
Contract manufacturing revenue		24,504		23,359		19,835
Total net sales	$	545,744	$	655,407	$	684,563

Summary of products which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2020		2019		2018
Product 1	18	%	10	%	8	%
Product 2	10	%	—	%	—	%
Product 3	—	%	30	%	36	%

Summary of customers which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2020		2019		2018
Customer A	25	%	21	%	29	%
Customer B	23	%	18	%	17	%
Customer C	11	%	10	%	5	%
Customer D	—	%	12	%	—	%